AUS
NZ
UK
CA
USA
IND
Highlight
- Major Contract Win: hLAB signs a £2.7m contract for a Phase 2 influenza drug trial, bringing the project's total value to £3.2m.
- International Scope: hLAB to support a multi-site Phase 2 study involving 5,000 subjects.
- Expanded Laboratory Capacity: Tripled capacity at Canary Wharf enables hLAB to offer standalone virology and immunology services.
hVIVO plc (LSE:HVO), a global leader in human challenge clinical trials and specialist contract research organisation (CRO), has announced a significant milestone for its standalone virology and immunology lab service provider, hLAB. The laboratory division has secured a £2.7m contract with a US-based biotechnology client, bringing the total value of this project to £3.2m.
Supporting a Major Influenza Drug Trial
Under the contract, hLAB will serve as the exclusive virology lab for a large-scale Phase 2 international field study evaluating an influenza drug candidate. The study will recruit 5,000 participants, and hLAB will provide critical virology and immunology laboratory services throughout the trial.
Work on the project has commenced immediately, with the bulk of the revenue expected to be recognised in 2025, followed by the remainder in 2026. Notably, this marks the largest standalone laboratory services contract in hVIVO’s history, underscoring the company’s growing prominence in the global virology and immunology space.
hLAB’s Expanded Capabilities
hLAB boasts over 20 years of experience in virology and immunology testing, primarily supporting hVIVO’s internal human challenge trials. With the company’s recent relocation to a new facility at Canary Wharf, laboratory capacity has tripled, enabling hLAB to offer its specialised services as standalone solutions to external clients.
These expanded capabilities include assay development, transfer and optimisation, sample handling, and processing through its biobank facility. This flexibility has positioned hLAB as a go-to partner for preclinical and clinical drug development in infectious and respiratory diseases.
